Bile acids for primary sclerosing cholangitis (Q24248730)

primary sclerosing cholangitis

inferred from title

1 reference

2

C Gluud

C

Gluud

1 reference

PubMed

PubMed publication ID

20 October 2023

Wendong Chen

1

W

Chen

1 reference

PubMed

PubMed publication ID

12804480

Cochrane Database of Systematic Reviews

20 October 2023

publication date

22 April 2003

0 references

published in

0 references

cites work

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Mechanisms of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Recent advances in the management of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Small-duct primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Bile acids, liver injury, and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties--studies on isolated hepatocytes and lipid membrane vesicles

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Sclerosing cholangitis: broad spectrum of radiographic features

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Current concepts. Primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021

A revised natural history model for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626

7 January 2021